Preserving the little things that mean everything

Colton
Received ELEVIDYS in 2024

The one-time treatment that helps preserve everyday abilities*

Keep moving forward

*As measured by the impact on motor function over time (vs placebo at 1 year and external control over 3 years) for North Star Ambulatory Assessment, time to rise from the floor, and time to walk/run 10 meters. Additional assessments at 3 years are considered exploratory. Talk to your doctor to learn more.

IMPORTANT SAFETY INFORMATION

What is the most important information to know about ELEVIDYS?

Rapid Serious Liver Injury and Rapid Liver Failure

- **ELEVIDYS can increase certain liver lab test levels and cause rapid serious liver injury, rapid liver failure, and death.** Patients with preexisting liver problems may be at higher risk.
- Complication of blood clots in the blood vessel in the abdomen that helps carry blood from the intestines to the liver has happened.
- Patients will receive oral corticosteroid medication before and after ELEVIDYS infusion and will need weekly blood tests to monitor liver function for 3 months or longer after treatment.
- For at least 2 months following ELEVIDYS infusion, stay close to a healthcare facility that the doctor recommends.
- Contact a doctor immediately if the patient's skin and/or whites of the eyes appear yellowish or if the patient misses a dose of corticosteroid or vomits it up.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

What is ELEVIDYS?

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the *DMD* gene.

ELEVIDYS is not recommended for individuals with:

- Preexisting liver problems or liver infection because of the high risk of rapid serious liver injury and rapid liver failure
- Recent vaccination (within 4 weeks of ELEVIDYS treatment)
- Current or recent infections (within 4 weeks of ELEVIDYS treatment)

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Jaylen
Received ELEVIDYS
in 2019*

The ELEVIDYS impact

the only FDA-approved gene therapy

- Proven to produce **ELEVIDYS micro-dystrophin**
- Demonstrated **impact on motor function**
- Safety information from **150+ clinical trial participants**
- A **monitoring plan** informed by FDA guidance and Duchenne experts
- **Dedicated support** for every step of your treatment journey

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Serious Infection

- Because patients will be taking corticosteroids as part of ELEVIDYS treatment, this may lower the ability of their immune system to fight infections and make it easier to get an infection. Getting an infection (like a cold, flu, stomach flu, ear infection, chest infection) before or after ELEVIDYS infusion could lead to more serious health problems, including death.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

* Clinical trial participant.

1,000+
families have said YES to ELEVIDYS*

* Includes worldwide clinical trial and US commercial use through November 2025.

"Jaxson is riding a bike, which made me cry. It's nice to cry about the good, happy things."

Angela, whose son Jaxson received ELEVIDYS

"Julius walks 2 blocks to the bus stop on his own — that's big for us."

Matthew, whose son Julius received ELEVIDYS

Individual results may vary.

"We've noticed that Jason isn't falling as much, and he's so proud of himself."

Sylvia, whose son Jason received ELEVIDYS

Visit ELEVIDYS.com/connections to speak with ELEVIDYS families!

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Serious Infection (continued)

- Contact a doctor right away if you notice any signs of infection, such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.
- Vaccinations should be completed at least 4 weeks before starting the corticosteroids that are part of the ELEVIDYS treatment.
- ELEVIDYS should not be given to patients with an infection.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

ELEVIDYS was studied in 200+ ambulatory people with a range of genetic mutations

STUDY 1

41
AMBULATORY PARTICIPANTS

4-7
YEARS OLD

Placebo-controlled trial*

2-part trial, with each part lasting 48 weeks

MAIN GOALS WERE TO MEASURE:

- ELEVIDYS micro-dystrophin
- Impact on motor function required for everyday movements
- Safety

STUDY 2 (also called "ENDEAVOR")

40
AMBULATORY PARTICIPANTS

3-12
YEARS OLD

Open-label trial†

MAIN GOALS WERE TO MEASURE:

- ELEVIDYS micro-dystrophin
- Safety

STUDY 3 (also called "EMBARK")

125
AMBULATORY PARTICIPANTS

4-7
YEARS OLD

Placebo-controlled trial*

2-part trial, with each part lasting 52 weeks

MAIN GOALS WERE TO MEASURE:

- Impact on motor function required for everyday movements 1 year after ELEVIDYS
- Safety

ADDITIONAL ASSESSMENTS:

Additional assessments on everyday movements were gathered 3 years after treatment with ELEVIDYS. These exploratory results help researchers learn about ELEVIDYS over time. Although they suggest positive trends, more data are needed to confirm the result. Talk to your doctor to learn more.

See pages 12-13 to learn how the impact of ELEVIDYS on everyday movements was measured.

Ongoing studies continue to track the impact of ELEVIDYS over time

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Inflammation of the Heart Muscle

- Serious and life-threatening inflammation of the heart muscle has happened following ELEVIDYS infusion.
- Patients will need weekly blood tests for a heart protein that can detect damage to the heart muscle cells for the first month after treatment.
- Contact a doctor right away if the patient begins to experience chest pain and/or trouble breathing or shortness of breath.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

* A placebo-controlled trial includes the medication being studied and a placebo, a substance that has no active medication. Results are then compared.

† In an open-label trial, all participants know that they are taking the medication being studied.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

In people with Duchenne, muscle loss is caused by a lack of dystrophin

Duchenne is caused by a change that happens in the dystrophin gene before birth. **This change stops the body from making dystrophin, a protein needed for muscles to work properly.**

Without dystrophin, muscles become irreversibly damaged. Over time, this leads to **ongoing loss of muscle strength**, making it difficult to walk and perform everyday activities.



Early intervention may help slow muscle damage. Talk to your doctor about a treatment plan that includes therapy to increase dystrophin

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Infusion-related Reactions

- Infusion-related reactions, including hypersensitivity and serious allergic reactions (anaphylaxis), have happened during and after ELEVIDYS infusion.
- Contact a doctor right away if you notice: fast heart rate, fast breathing, swollen lips, shortness of breath, nostrils widening, hives, red and blotchy skin, itchy or inflamed lips, rash, vomiting, nausea, chills, and fever.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

ELEVIDYS delivers a new version of dystrophin to the body

ELEVIDYS instructs the body to make a new, shorter version of dystrophin, called ELEVIDYS micro-dystrophin.

This new version is similar to the body's natural dystrophin. While not exactly the same, it helps protect muscles from damage.

To learn more about how ELEVIDYS works, visit ELEVIDYS.com

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Proven to produce ELEVIDYS micro-dystrophin



MAIN MEASURE

3 MONTHS AFTER ELEVIDYS

↑34% TO 51%

average increase in ELEVIDYS micro-dystrophin†

ADDITIONAL ASSESSMENTS*

16 MONTHS AFTER ELEVIDYS

↑46%

average increase in ELEVIDYS micro-dystrophin‡

The average increase in ELEVIDYS micro-dystrophin was **consistent**

People with Duchenne who are untreated typically have **little to no dystrophin**

* Additional assessments are considered exploratory. Talk to your doctor to learn more.

† Results from Study 1 Part 1 (6 participants), Study 1 Part 2 (21 participants), Study 2 (40 participants), and Study 3 (17 participants). In Study 3, since people receiving placebo (14 participants) did not receive ELEVIDYS, they had 0% ELEVIDYS micro-dystrophin.

‡ Results from Study 3 (16 participants).

Max
Received ELEVIDYS
in 2020§

Fuel the moments that **matter most**

Duchenne affects each person differently.
Individual results may vary.

§Clinical trial participant.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Infusion-related Reactions (continued)

- Your doctor will monitor you during and at least 3 hours after ELEVIDYS infusion. If an infusion-related reaction occurs, your doctor may slow or stop the ELEVIDYS infusion and provide additional medical treatment as needed.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Multiple tools measured the impact of ELEVIDYS on everyday movements

NSAA

The **North Star Ambulatory Assessment** looks at how well participants can **perform everyday movements**, including 17 different activities (shown below). **Each movement is scored on a scale of 0 to 2**, where 0 means the person cannot complete the movement at all, 1 means they require help, and 2 means they can accomplish it independently. These scores were checked at different points during the study to track changes over time. **If a score increases by 1 or 2 points, it means a person maintained or improved their ability to perform a movement.**



TTR

Time to rise is a test that assesses how quickly a person can **stand up from lying on their back**.

10MWR

10-meter walk/run is a test that assesses how quickly a person can **walk or run 10 meters (about 30 feet)**.

Participants' speed was measured at specific time points throughout the study. **These tests help doctors predict when a child may lose the ability to walk.**

Evaluating these results

To understand the impact of ELEVIDYS, researchers compared the results from people who received ELEVIDYS in Study 3 ("EMBARK") with 2 other groups who did not receive ELEVIDYS. All participants were on stable doses of steroids at the start of the trial regardless of whether or not they received ELEVIDYS.

ELEVIDYS

VS

Placebo

These Study 3 ("EMBARK") participants did not receive ELEVIDYS. Instead, they were given a placebo, which is a treatment with no real medicine in it. Results were measured at 1 year and compared with results in people who received ELEVIDYS.

External control

These individuals did not receive ELEVIDYS or participate in Study 3 ("EMBARK") but had both Duchenne and similar characteristics (for example, age, physical ability) to those who did. Results were measured at 3 years and compared with results in people who received ELEVIDYS.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Immune Response Affecting Muscles (Immune-mediated Myositis)

- Immune response affecting muscles, including serious and life-threatening reactions, has happened in patients about 1 month after receiving ELEVIDYS infusion.
- Contact a doctor immediately if the patient experiences any unexplained increased muscle pain, tenderness, or weakness, including trouble swallowing, breathing, or speaking.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

With ELEVIDYS, participants scored higher on tests that measure everyday movements

NSAA

NORTH STAR AMBULATORY ASSESSMENT (NSAA)

MAIN MEASURE

1 YEAR AFTER ELEVIDYS

With ELEVIDYS, movement scores were

0.7 points higher

vs placebo† in 4 to 7-year-olds

The difference was not statistically significant.

ADDITIONAL ASSESSMENTS*

3 YEARS AFTER ELEVIDYS

With ELEVIDYS, movement scores were

4.39 points higher

vs external control† in 7 to 10-year-olds

*Additional assessments are considered exploratory. Talk to your doctor to learn more.

†As measured by the average change in NSAA score.

All participants had similar characteristics (eg, age, physical ability) at the start of the study and were on stable doses of steroids.

Thomas
Received ELEVIDYS in 2022‡

‡Clinical trial participant.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information to know about ELEVIDYS? (continued)

Antibodies to ELEVIDYS

- Patients need to have blood tests to ensure that they do not have antibodies that may prevent them from being able to receive ELEVIDYS. High levels of antibodies may keep the medicine from working as intended.
- Treatment with ELEVIDYS is not recommended for patients who have high antibodies to the vector, the part of gene therapy used to deliver ELEVIDYS.

You should discuss the potential benefits and risks of ELEVIDYS with your doctor.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

With ELEVIDYS, participants got up from the floor faster

TIME TO RISE

1 YEAR AFTER ELEVIDYS

MAIN MEASURE

0.64 seconds *faster*

with **ELEVIDYS** vs placebo† in 4 to 7-year-olds

3 YEARS AFTER ELEVIDYS

ADDITIONAL ASSESSMENTS*

6.05 seconds *faster*

with **ELEVIDYS** vs external control† in 7 to 10-year-olds

Getting up from the floor faster after treatment suggests a delay in disease progression

*Additional assessments are considered exploratory. Talk to your doctor to learn more.

†As measured by the average change in time to rise from the floor.

All participants had similar characteristics (eg, age, physical ability) at the start of the study and were on stable doses of steroids.

‡Clinical trial participant.

IMPORTANT SAFETY INFORMATION (continued)

Who should not receive ELEVIDYS?

Individuals with a certain type of genetic mutation, called a deletion, involving any portion of or the entire exon 8 and/or exon 9 in the *DMD* gene, should not receive ELEVIDYS.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

With ELEVIDYS, participants walked or ran faster

10-METER WALK/RUN

1 YEAR AFTER ELEVIDYS

MAIN MEASURE

with **ELEVIDYS** vs placebo† in 4 to 7-year-olds

3 YEARS AFTER ELEVIDYS

ADDITIONAL ASSESSMENTS*

with **ELEVIDYS** vs external control† in 7 to 10-year-olds

Walking/running faster after treatment suggests a delay in disease progression

*Additional assessments are considered exploratory. Talk to your doctor to learn more.

†As measured by the average change in 10-meter walk/run time.

All participants had similar characteristics (eg, age, physical ability) at the start of the study and were on stable doses of steroids.

Andrew
Received ELEVIDYS in 2019‡

‡Clinical trial participant.

IMPORTANT SAFETY INFORMATION (continued)

Are there any considerations for vaccination schedules and ELEVIDYS?

Patient vaccinations should be up to date with current immunization guidelines. Vaccinations should be completed at least 4 weeks before starting corticosteroids that are part of the ELEVIDYS treatment.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

ELEVIDYS impact on muscle loss, measured by the amount of fat in muscles

In people with Duchenne, damaged muscle cells are replaced by fat cells over time. To help assess the impact of ELEVIDYS, researchers measured the change in fat within 5 muscle groups in the arms and legs. After 1 year, results were compared between people who received ELEVIDYS and those who received placebo.

These images show results from 2 participants in the clinical trial: one received ELEVIDYS and the other received placebo.

Muscle vs fat deposit as measured by MRI after 1 year

WITH ELEVIDYS



TRIAL START	1 YEAR
7.4%	6.4%

WITH PLACEBO



TRIAL START	1 YEAR
7.7%	10.7%

UNDERSTANDING THESE RESULTS

- Magnetic resonance imaging (MRI) is used to show the difference between muscle and fat in the body
- The arrows in the image on the lower right point to new fat deposits in the thigh muscle after 1 year
- These additional results are from a smaller group of trial participants. These exploratory results help researchers learn about ELEVIDYS. More data are needed to confirm the result. Talk to your doctor to learn more

Colton
Received ELEVIDYS in 2024

IMPORTANT SAFETY INFORMATION (continued)

Are there any precautions that need to be considered when handling a patient's bodily waste?

Vector shedding of ELEVIDYS occurs primarily through body waste. Patients and caregivers should use proper hand hygiene, such as hand washing, when coming into direct contact with patient body waste. Place potentially contaminated materials that may have the patient's bodily fluids/waste in a sealable bag and dispose into regular trash. Precautions should be followed for 1 month after ELEVIDYS infusion.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

ELEVIDYS slowed disease progression*

Based on multiple measures of everyday movements, results show:

ELEVIDYS helped people
score *higher* on tests of everyday movements

ELEVIDYS helped people
get up from the floor *faster*

ELEVIDYS helped people
walk/run *faster*

Results were measured up to **3 years after treatment**

*Results were assessed at 1 year vs placebo and at 3 years vs external control. Additional assessments at 3 years are considered exploratory. Talk to your doctor to learn more.

IMPORTANT SAFETY INFORMATION (continued)

What are the most common side effects of ELEVIDYS?

The most common side effects that occurred in patients treated with ELEVIDYS were vomiting, nausea, liver injury, fever, lower number of platelets (a kind of blood cell that helps you stop bleeding), and higher levels of heart protein that can detect damage to muscle cells in the heart.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Important Safety Information

What is the most important information to know about ELEVIDYS?

Rapid Serious Liver Injury and Rapid Liver Failure

- **ELEVIDYS can increase certain liver lab test levels and cause rapid serious liver injury, rapid liver failure, and death.** Patients with preexisting liver problems may be at higher risk.
- Complication of blood clots in the blood vessel in the abdomen that helps carry blood from the intestines to the liver has happened.
- Patients will receive oral corticosteroid medication before and after ELEVIDYS infusion and will need weekly blood tests to monitor liver function for 3 months or longer after treatment.
- For at least 2 months following ELEVIDYS infusion, stay close to a healthcare facility that the doctor recommends.
- Contact a doctor immediately if the patient's skin and/or whites of the eyes appear yellowish or if the patient misses a dose of corticosteroid or vomits it up.

Serious Infection

- Because patients will be taking corticosteroids as part of ELEVIDYS treatment, this may lower the ability of their immune system to fight infections and make it easier to get an infection. Getting an infection (like a cold, flu, stomach flu, ear infection, chest infection) before or after ELEVIDYS infusion could lead to more serious health problems, including death.
- Contact a doctor right away if you notice any signs of infection, such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.
- Vaccinations should be completed at least 4 weeks before starting the corticosteroids that are part of the ELEVIDYS treatment.
- ELEVIDYS should not be given to patients with an infection.

Inflammation of the Heart Muscle

- Serious and life-threatening inflammation of the heart muscle has happened following ELEVIDYS infusion.
- Patients will need weekly blood tests for a heart protein that can detect damage to the heart muscle cells for the first month after treatment.
- Contact a doctor right away if the patient begins to experience chest pain and/or trouble breathing or shortness of breath.

Infusion-related Reactions

- Infusion-related reactions, including hypersensitivity and serious allergic reactions (anaphylaxis), have happened during and after ELEVIDYS infusion.
- Contact a doctor right away if you notice: fast heart rate, fast breathing, swollen lips, shortness of breath, nostrils widening, hives, red and blotchy skin, itchy or inflamed lips, rash, vomiting, nausea, chills, and fever.
- Your doctor will monitor you during and at least 3 hours after ELEVIDYS infusion. If an infusion-related reaction occurs, your doctor may slow or stop the ELEVIDYS infusion and provide additional medical treatment as needed.

What is the most important information to know about ELEVIDYS? (continued)

Immune Response Affecting Muscles (Immune-mediated Myositis)

- Immune response affecting muscles, including serious and life-threatening reactions, has happened in patients about 1 month after receiving ELEVIDYS infusion.
- Contact a doctor immediately if the patient experiences any unexplained increased muscle pain, tenderness, or weakness, including trouble swallowing, breathing, or speaking.

Antibodies to ELEVIDYS

- Patients need to have blood tests to ensure that they do not have antibodies that may prevent them from being able to receive ELEVIDYS. High levels of antibodies may keep the medicine from working as intended.
- Treatment with ELEVIDYS is not recommended for patients who have high antibodies to the vector, the part of gene therapy used to deliver ELEVIDYS.

You should discuss the potential benefits and risks of ELEVIDYS with your doctor.

Who should not receive ELEVIDYS?

Individuals with a certain type of genetic mutation, called a deletion, involving any portion of or the entire exon 8 and/or exon 9 in the *DMD* gene, should not receive ELEVIDYS.

Are there any considerations for vaccination schedules and ELEVIDYS?

Patient vaccinations should be up to date with current immunization guidelines. Vaccinations should be completed at least 4 weeks before starting corticosteroids that are part of the ELEVIDYS treatment.

Are there any precautions that need to be considered when handling a patient's bodily waste?

Vector shedding of ELEVIDYS occurs primarily through body waste. Patients and caregivers should use proper hand hygiene, such as hand washing, when coming into direct contact with patient body waste. Place potentially contaminated materials that may have the patient's bodily fluids/waste in a sealable bag and dispose into regular trash. Precautions should be followed for 1 month after ELEVIDYS infusion.

What are the most common side effects of ELEVIDYS?

The most common side effects that occurred in patients treated with ELEVIDYS were vomiting, nausea, liver injury, fever, lower number of platelets (a kind of blood cell that helps you stop bleeding), and higher levels of heart protein that can detect damage to muscle cells in the heart.

The safety information provided here is not comprehensive. Talk to the patient's doctor about any side effects that bother the patient or that don't go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Austin
Received ELEVIDYS in 2021*

*Clinical trial participant.

Safety measured in more than 150 people

The most common side effects typically occur in the first 2 weeks and include vomiting (as early as on infusion day), nausea, fever, and low platelet count.

Additional side effects that could occur include:

- **Within the first month:** inflammation of the heart (myocarditis) and increase in troponin-I, a cardiac protein that can indicate damage to muscle cells in the heart
- **Within the first 2 months:** an immune response affecting muscles (immune-mediated myositis) and liver injury

Side effects in Study 3 when compared with the placebo group

Side effect	ELEVIDYS n=63	Placebo n=62
Vomiting	64%	19%
Nausea	40%	13%
Liver injury	41%	8%
Fever	32%	24%
Low platelet count	3%	0%

- Most side effects occurred within 3 months of treatment with ELEVIDYS, and no new safety concerns have been observed 3 years after treatment
- Talk to your child's doctor about all the possible side effects of ELEVIDYS

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

A careful treatment and monitoring process informed by the FDA and Duchenne experts

ELEVIDYS is not recommended for those with preexisting liver problems, recent vaccinations (within 4 weeks), or current/recent infections (within 4 weeks).

CONFIRM ELIGIBILITY

You'll need:

- A genetic test
- An ELEVIDYS-specific antibody test
- Additional tests that your doctor may consider important

Your child may not be eligible for ELEVIDYS based on these results. ELEVIDYS cannot be used in anyone with a whole or partial deletion in exon 8 and/or exon 9 of the *DMD* gene.

PREPARE FOR TREATMENT

Your child will need to remain close to an appropriate healthcare facility for at least 2 months after treatment. You can work with your doctor to find the right facility for this ongoing monitoring.

Start oral treatment-related steroids just before ELEVIDYS to help reduce the likelihood of side effects. These are in addition to steroids your child may already take.

Talk with your doctor about what to expect from treatment based on your starting point. The progression of Duchenne is different for each person.

TREATMENT DAY

The care team at the treatment center will closely watch for any infusion-related reactions for at least 3 hours after treatment.

DURING THE FIRST 3 MONTHS

Your child will have doctor's exams and weekly blood tests to check:

- Liver function (weekly for 3 months)
- Platelet counts (weekly for 2 weeks)
- Troponin-I levels (weekly for 1 month)

Longer or more frequent monitoring may be needed, depending on your child's test results.

During this time, taking oral treatment-related steroids will help reduce the risk of an immune response.*

Learn more about the treatment journey at ELEVIDYS.com

*Your doctor may adjust this length of time — or the dose — based on the person's response to ELEVIDYS, including helping address any changes in liver function tests. It's important to follow your doctor's advice on ELEVIDYS treatment-related steroids, including during the tapering period.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

A community of support

ELEVIDYS Community Connections
provides families who are considering treatment an opportunity to connect directly with other parents whose children have received ELEVIDYS

- Hear firsthand about their experience with ELEVIDYS
- Ask them questions
- Learn more about the treatment process

Visit ELEVIDYS.com/connections to connect today

Sarepta offers support throughout the treatment journey

Choosing a treatment for Duchenne is an important decision that comes with a lot of questions. We're here to help.

Our Patient Education Liaisons can help you:

- Get answers to questions about ELEVIDYS
- Learn more about what to expect with treatment
- Prepare for a discussion with your doctor
- Access helpful resources

Connect with a Patient Education Liaison today!

PatientEducation@Sarepta.com

1-888-848-6374

Our SareptAssist team can help you:

- Explore insurance benefits
- Consider financial assistance options
- Facilitate appointments and logistics

SareptAssist is a resource available only to those in the US who have been prescribed ELEVIDYS.

Patient Education Liaisons (PELs) do not provide medical advice and are not a substitute for your medical team. Always be sure to talk to your doctor first about any questions about your medical care.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion

Keep his momentum going with ELEVIDYS



Thomas
Received ELEVIDYS in 2022*

- Proven to produce **ELEVIDYS micro-dystrophin**
- Demonstrated **impact on motor function**
- Treatment with ELEVIDYS **slowed disease progression**
- Safety information from **150+ clinical trial participants**
- A **monitoring plan** informed by FDA guidance and Duchenne experts
- **Dedicated support** for every step of your treatment journey

A community

1,000+ strong†

* Clinical trial participant.

† Includes worldwide clinical trial and US commercial patient use through November 2025.

IMPORTANT SAFETY INFORMATION (continued)

What are the most common side effects of ELEVIDYS? (continued)

The safety information provided here is not comprehensive. Talk to the patient's doctor about any side effects that bother the patient or that don't go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.

SAREPTA THERAPEUTICS

Elevidys
delandistrogene moxeparvovec-rokl
suspension for intravenous infusion